NEW YORK (AP) — Actavis said Tuesday that the Food and Drug Administration didn't approve its progestin-only contraceptive patch and wants more information on the drug. The company said the FDA's questions are mostly regarding the drug's size and formulation. Actavis used one size and formulation in clinical trials and wants to market a different version. Most birth control drugs use a combination of two female hormones, estrogen and progestin. The company's patch contains only progestin. U.S.-traded shares of Ireland -based Actavis PLC fell $1.41 to $164.55 in morning trading.
Most Popular Stories
- Photo ID Required for Unemployment Benefits
- Software Writers Sought in Indiana
- Ukraine Crisis Limits Losses in Gold, Silver
- Can GOP Dodge Immigration Bullet?
- How Past Mistakes Will Drive Ukraine's Future
- Tech Firms to Increase Hiring for 4th Year in a Row
- Job Fair for S.C. Grads
- Chiquita, Fyffes to Form Top Banana
- Millennials Favor Saving Over Investing: UBS
- Big Earthquake Rumbles Northern California